James E. Shields
Direttore/Membro del Consiglio presso Allos Therapeutics, Inc.
Profilo
James E.
Shields is currently a Director at Allos Therapeutics, Inc. Previously, he was the Chief Commercial Officer & Senior Vice President at Spectrum Pharmaceuticals, Inc. He received his undergraduate degree from the University of Kentucky.
Posizioni attive di James E. Shields
| Società | Posizione | Inizio |
|---|---|---|
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Direttore/Membro del Consiglio | 05/09/2012 |
Precedenti posizioni note di James E. Shields
| Società | Posizione | Fine |
|---|---|---|
| SPECTRUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 29/10/2012 |
Formazione di James E. Shields
| University of Kentucky | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| SPECTRUM PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
- Borsa valori
- Insiders
- James E. Shields